WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Employees

12,575

Sector

Biotechnology & Medical Research

Calendar

08-24 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-14	26.75 $	+0.38%	38,433,127
25-07-11	26.65 $	+3.70%	99,116,310
25-07-10	25.70 $	-0.77%	21,149,810
25-07-09	25.90 $	+0.78%	40,298,040
25-07-08	25.70 $	+2.59%	48,003,420

Delayed Quote Hong Kong S.E., July 14, 2025 at 02:41 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

AAA

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

24.34CNY

Average target price

27.30CNY

Spread / Average Target

+12.16%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2025-07-14 EDT			5-day change	1st Jan Change
26.75 ^HKD	+0.38%		+6.79%	+52.33%

06-30	WuXi Biologics Launches Next-Generation Platform WuXiHigh??2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	CI
06-18	US-China Tensions Cause Delay in Chinese Drug Research Projects, Sources Say	MT

Capitalization	99.03B 108B 13.81B 11.81B 11B 10.23B 18.91B 1,185B 21.01B 132B 50.41B 555B 51.81B 50.74B 2,036B	P/E ratio 2025 *	25.2x	P/E ratio 2026 *	21.4x
Enterprise value	93.97B 103B 13.11B 11.21B 10.44B 9.71B 17.94B 1,125B 19.94B 125B 47.83B 527B 49.16B 48.15B 1,932B	EV / Sales 2025 *	4.43x	EV / Sales 2026 *	3.8x
Free-Float	86.37%	Yield 2025 *	-	Yield 2026 *	-

WuXi Biologics Launches Next-Generation Platform WuXiHigh??2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	06-30	CI
US-China Tensions Cause Delay in Chinese Drug Research Projects, Sources Say	06-18	MT
China pharma projects disrupted by Sino-US tensions	06-17	RE
Hong Kong Stocks Edge Higher Despite Mixed China Data; Wuxi Biologics Drops on Stake Sale	06-16	MT
WuXi Biologics Shareholder to Offload 2% Stake via Block Trade; Shares Slide 6%	06-16	MT
Wuxi Biologics Announces Placing Of Existing Shares By Substantial Shareholder	06-15	RE
WuXi Biologics Kicks Off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu	06-09	CI
Wuxi Biologics Inc. Announces Directorate Changes, Effective June 6, 2025	06-06	CI
Wuxi Biologics Appoints Sherry Xuejun Gu As An Executive Director	06-06	RE
WuXi Biologics Grants 64,117 Restricted Shares Under Incentive Scheme	06-05	MT
Hong Kong Stocks Jump as US Court Blocks Trump's Tariffs; WuXi Biologics Surges 10%	05-29	MT
Terumo Says It And Wuxi Biologics Enter Into Agreement On A Drug Product Plant In Leverkusen, Germany	05-14	RE
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs	05-11	DJ

Jefferies Adjusts WuXi Biologics (Cayman)'s Price Target to HK$45 From HK$35, Keeps at Buy	03-31	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$34.36 From HK$30.59, Keeps at Buy	03-26	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$30.59 From HK$19.30, Keeps at Buy	02-20	MT
UOB Kay Hian Upgrades Wuxi Biologics to Buy from Sell, Price Target is HK$23	02-04	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$19.30 From HK$23.25, Keeps at Buy	24-08-22	MT

WuXi Biologics (Cayman) Inc. Stock

Equities

2269

KYG970081173

Biotechnology & Medical Research

Valuation: WuXi Biologics (Cayman) Inc.

Chart: WuXi Biologics (Cayman) Inc.

Latest news: WuXi Biologics (Cayman) Inc.

Last Transcript: WuXi Biologics (Cayman) Inc.

Analysts' recommendations: WuXi Biologics (Cayman) Inc.

Press Releases: WuXi Biologics (Cayman) Inc.

News in other languages: WuXi Biologics (Cayman) Inc.

Quotes and Performance

Course Extremes

Managers and Directors: WuXi Biologics (Cayman) Inc.

ETFs: WuXi Biologics (Cayman) Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

WuXi Biologics Launches Next-Generation Platform WuXiHigh2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	06-30	AQ
WuXi Biologics Cayman : Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL	06-29	PU
WuXi Biologics Cayman : Included in MSCI Selection Indexes for Third Consecutive Year	06-19	PU
Construction begins on new WuXi microbial manufacturing site	06-10	AQ
WuXi Biologics Cayman : and Virogen Biotechnology Establish Commercial Manufacturing Partnership	06-09	PU

La china WuXi Biologics venderá a Merck sus instalaciones de vacunas en Irlanda por 500 millones de dólares	01-06
MÄRKTE ASIEN/Honkgong nimmt wieder Fahrt nach oben auf	24-10-04
MÄRKTE ASIEN/Uneinheitlich - Anleger halten sich vor US-Daten zurück	24-09-10
MÄRKTE ASIEN/Etwas fester - US-Biotech-Gesetz belastet in China	24-09-10
MÄRKTE ASIEN/Yen auf 34-Jahres-Tief stützt Kurse in Tokio	24-03-27

1 day	+0.56%
1 week	+6.99%
Current month	+4.48%
1 month	+1.13%
3 months	+26.42%
6 months	+52.27%
Current year	+52.62%

1 week	24.65	27.5
1 month	23.1	27.5
Current year	15.62	29.3
1 year	10.14	29.3
3 years	10.14	82.95
5 years	10.14	148
10 years	8.33	148

Manager	Title	Age	Since
Zhi Sheng Chen CEO	Chief Executive Officer	53	2015-12-31
Ming Tu DFI	Director of Finance/CFO	55	2021-08-22
Ji Jie Gu CTO	Chief Tech/Sci/R&D Officer	58	-

Director	Title	Age	Since
Ge Li CHM	Chairman	57	2014-01-31
Zhi Sheng Chen BRD	Director/Board Member	53	2014-01-31
Yan Ling Cao BRD	Director/Board Member	40	2016-04-30

Name	Weight	AuM	1st Jan change
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	9.62%	0 M€	-19.71%	-
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD	4.23%	0 M€	-3.45%	-
CIMB FTSE CHINA 50 ETF - MYR	2.99%	1 M€	+11.52%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
WUXI BIOLOGICS (CAYMAN) INC.	+0.56%	+6.99%	+141.88%	-66.27%	13.81B
ARGENX SE	-1.01%	+2.87%	+11.41%	+34.18%	34.39B
WUXI APPTEC CO., LTD.	+9.99%	+8.94%	+98.84%	-27.18%	30.84B
BIONTECH SE	-0.90%	+2.63%	+32.89%	-32.25%	27.8B
INSMED INCORPORATED	+1.57%	+0.39%	+27.99%	+322.28%	18.65B
SUMMIT THERAPEUTICS INC.	-3.40%	+1.83%	+192.40%	+2,524.95%	18.57B
GENMAB A/S	-1.18%	+6.12%	-25.33%	-45.19%	13.28B
AKESO, INC.	+4.42%	+4.07%	+205.06%	+393.08%	12.94B
EXELIXIS, INC.	-0.69%	-2.80%	+100.27%	+107.40%	12.23B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.12%	-3.29%	+127.20%	-	9.9B
Average	+0.91%	+1.47%	+91.26%	+356.78%	19.24B
Weighted average by Cap.	+1.30%	+2.67%	+79.06%	+313.48%

	2025 *	2026 *
Net sales	21.22B 23.24B 2.96B 2.53B 2.36B 2.19B 4.05B 254B 4.5B 28.26B 10.8B 119B 11.1B 10.88B 436B	24.37B 26.68B 3.4B 2.91B 2.71B 2.52B 4.65B 292B 5.17B 32.44B 12.4B 137B 12.75B 12.49B 501B
Net income	4B 4.38B 558M 478M 445M 414M 764M 47.91B 849M 5.33B 2.04B 22.43B 2.09B 2.05B 82.29B	4.74B 5.19B 661M 565M 527M 490M 905M 56.72B 1.01B 6.31B 2.41B 26.56B 2.48B 2.43B 97.41B
Net Debt	-5.06B -5.54B -706M -604M -562M -523M -966M -60.57B -1.07B -6.74B -2.58B -28.36B -2.65B -2.59B -104B	-6.42B -7.03B -896M -766M -714M -664M -1.23B -76.86B -1.36B -8.55B -3.27B -35.99B -3.36B -3.29B -132B